Novoron Bioscience’s CEO, Travis Stiles, Ph.D., to Present at the 2025 Biocom Global Life Science Partnering and Investor Conference
Novoron Bioscience Welcomes Dr. David Weiner to the Board of Directors
Novoron Bioscience is excited to announce that Dr. David Weiner is the newest member of the Board of Directors.
Novoron Bioscience To Present at BIO 2024 Conference
Novoron Bioscience, a San Diego-based biotechnology company developing first-in-class therapies to reverse central nervous system (CNS) damage, will be participating in a range of activities at the upcoming BIO 2024 conference.
Novoron Bioscience Awarded NIH Grant for Research Into Alzheimer's Disease
Novoron Bioscience has received an NIH/NIA grant to advance its work on Alzheimer’s disease, CTE and other tauopathies.
Novoron Bioscience Raises $3M in Seed Financing from Two Bear Capital
Novoron Bioscience, a San Diego-based biotechnology company developing first-in-class therapies to reverse central nervous system (CNS) damage, announced today that they secured a $3 million Seed investment from Two Bear Capital (TBC).